Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses (Q45628437)

14 December 2017

title

Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses (English)

1 reference

Nagadenahalli Byrareddy Siddappa

14 December 2017

author

object named as

Nagadenahalli B Siddappa

6

0 references

author name string

Lakshmi Ramakrishna

1

1 reference

14 December 2017

Krishnamurthy Kumar Anand

2

1 reference

14 December 2017

Marthandan Mahalingam

3

1 reference

14 December 2017

Kumarasamypet M Mohankumar

4

1 reference

14 December 2017

Shilpa Ramani

5

1 reference

14 December 2017

Udaykumar Ranga

7

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

14 December 2017

1 reference

14 December 2017

volume

22

1 reference

14 December 2017

issue

20

1 reference

14 December 2017

page(s)

2586-2598

1 reference

14 December 2017

cites work

The HIV-1 vaccine race

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Codon usage patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a review of the considerable within-species diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

DNA sequence evolution: the sounds of silence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Codon usage tabulated from international DNA sequence databases: status for the year 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Secreted placental alkaline phosphatase as a eukaryotic reporter gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Tat toxoid as a component of a preventive vaccine in seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Tat-neutralizing antibodies in vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Vaccination with Rev and Tat against AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

HIV-1 genetic variability: implications for the development of HIV vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

inferred from DOI database lookup

7 January 2021

based on heuristic

DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.12.007

1 reference

14 December 2017

1 reference